OncoSec Medical Company

OncoSec Medical Incorporated (OTCBB: ONCS) is an advanced-stage biomedical company focused on the development of novel therapeutic oncology products. Its mission, above all, is to improve the quality and performance of treatments for patients suffering from solid tumor cancers. This is driven by its unwavering commitment to improving the quality of lives of cancer patients through the use of innovative research and the advancement of new “ElectroOncolog” therapies based on its proprietary OncoSe Medical System (OMS). OncSec's core technology is an untapped delivery system, which applies short electric impulses to a tumor causing transient pores to open in the cellular membrane allowing therapeutic agents to more readily enter cancer cells. This process is known as OMS Electroporation. Using OMS Electroporation in tandem with chemotherapeutic or biologic agents can selectively and effectively treat cancerous tumors and cells embedded amongst predominantly healthy tissue. Its treatment approach also reduces and even eliminates much of the detrimental outcomes associated with other “standard of care” therapies readily available in the clinic today.
Technology: Apps
Industry: NeuroTech
Headquarters: United States
Founded Date: 2008-01-01
Employees Number: 51-100
Funding Status: IPO
Investors Number: 2
Total Funding: $93.8M
Estimated Revenue: $10M to $50M
Last Funding Type: Post-IPO Equity

Visit Website
investors@oncosec.com
http://twitter.com/Oncosec
Register and Claim Ownership